OneSource bets on weight-loss drugs, ups FY28 guidance

Backed by strong demand across its drug-device and biologics businesses, OneSource Speciality Pharma has raised its FY28 revenue guidance from $400 million to over $500 million, chief executive and managing director Neeraj Sharma told Mint in an interview.

- Jessica Jani

The company is also targeting an Ebitda margin of 40% from 28% reported in July-September.

The Bengaluru-based contract development and manufacturing organization's optimism largely stems from the expected surge in demand for semaglutide, known popularly by its brand name Ozempic, whose patents expire in key markets such as Canada, Brazil and India next year.